A Phase 1 interventional study of DWP14012 and DWC202202 in Drug Drug Interaction, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-04.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A randomized, open-label, three-sequence, three-period, multiple dosing crossover, phase 1 clinical trial to evaluate the effect of DWP14012 on the pharmacodynamics of DWC202202 in combination with DWP14012 in healthy subjects
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with a body weight ≥ 50.0 kg to ≤ 90.0 kg with a (BMI) of ≥ 18.0 kg/m2 to ≤ 27.0 kg/m2 at screening
※ BMI (kg/m2) = body weight (kg)/[height (m)]2
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Treatment A: DWC202202 1 tablet qd for 7days * Treatment B: DWC202202 1 tablet qd + DWP14012 1 tablet qd for 7days * Treatment C: DWC202202 1 tablet qd + DWC202203 1 tablet qd for 7days
Drug: DWP14012 · Drug: DWC202202 · Drug: DWC202203
* Treatment C: DWC202202 1 tablet qd + DWC202203 1 tablet qd for 7days * Treatment A: DWC202202 1 tablet qd for 7days * Treatment B: DWC202202 1 tablet qd + DWP14012 1 tablet qd for 7days
Drug: DWP14012 · Drug: DWC202202 · Drug: DWC202203
* Treatment B: DWC202202 1 tablet qd + DWP14012 1 tablet qd for 7days * Treatment C: DWC202202 1 tablet qd + DWC202203 1 tablet qd for 7days * Treatment A: DWC202202 1 tablet qd for 7days
Drug: DWP14012 · Drug: DWC202202 · Drug: DWC202203
Potassium-competitive acid blocker
Clopidogrel Bisulfate
Proton pump inhibitor
Emax
Time frame: up to 50 days
AUEC0-24
Time frame: up to 50 days
DWC202202 Cmax,ss
Time frame: up to 50 days
DWC202202 active metabolite Cmax,ss
Time frame: up to 50 days
DWC202202 AUCtau,ss
Time frame: up to 50 days
DWC202202 active metabolite AUCtau,ss
Time frame: up to 50 days
DWC202202 AUCinf,ss
Time frame: up to 50 days
DWC202202 active metabolite AUCinf,ss
Time frame: up to 50 days
DWC202202 Tmax,ss
Time frame: up to 50 days
DWC202202 active metabolite Tmax,ss
Time frame: up to 50 days
DWC202202 t1/2,ss
Time frame: up to 50 days
DWC202202 active metabolite t1/2,ss
Time frame: up to 50 days
DWC202202 Cmin,ss
Time frame: up to 50 days
DWC202202 active metabolite Cmin,ss
Time frame: up to 50 days
DWC202202 Cavg,ss
Time frame: up to 50 days
DWC202202 active metabolite Cavg,ss
Time frame: up to 50 days
DWC202202 CLss/F
Time frame: up to 50 days
DWC202202 Vd,ss/F
Time frame: up to 50 days
DWC202202 PTF (peak to trough fluctuation)
Time frame: up to 50 days
DWC202202 active metabolite PTF (peak to trough fluctuation)
Time frame: up to 50 days
DWC202202 R
Time frame: up to 50 days
DWC202202 active metabolite MR
Time frame: up to 50 days
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Sep 2022 to primary completion in Mar 2023, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fexuprazan
Daewoong Pharmaceutical Co. LTD. →